This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://localhost/temp/predkladatel/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/ontology/domain/vavai/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F14%3A00075516%21RIV15-MSM-14110___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F14%3A00075516%21RIV15-MSM-14110___
rdf:type
n14:Vysledek skos:Concept
dcterms:description
Introduction: In the treatment of bleeds in haemophilia patients with inhibitors, a high initial dose of recombinant Factor VIIa (rFVIIa) provides at least equal efficacy and a similar safety profile to a standard initial dose. However, no pharmacoeconomic comparison between these dosing regimens has previously been performed. Here, we assess the pharmacoeconomics of high (> 120 mu g/kg) versus standard (<= 120 mu g/kg) initial rFVIIa dose in inhibitor patients and the impact of time to treatment initiation on costs and outcomes. Methods: In a retrospective analysis, observational data on bleed characteristics, rFVIIa treatment, hospitalizations and outcomes were extracted from the Czech Republic HemoRec registry. Crude comparisons and generalized linear regression modelling (GLM; correcting for patient differences) were performed to compare costs and outcomes between the high and standard initial dosing groups. Introduction: In the treatment of bleeds in haemophilia patients with inhibitors, a high initial dose of recombinant Factor VIIa (rFVIIa) provides at least equal efficacy and a similar safety profile to a standard initial dose. However, no pharmacoeconomic comparison between these dosing regimens has previously been performed. Here, we assess the pharmacoeconomics of high (> 120 mu g/kg) versus standard (<= 120 mu g/kg) initial rFVIIa dose in inhibitor patients and the impact of time to treatment initiation on costs and outcomes. Methods: In a retrospective analysis, observational data on bleed characteristics, rFVIIa treatment, hospitalizations and outcomes were extracted from the Czech Republic HemoRec registry. Crude comparisons and generalized linear regression modelling (GLM; correcting for patient differences) were performed to compare costs and outcomes between the high and standard initial dosing groups.
dcterms:title
Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry
skos:prefLabel
Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry
skos:notation
RIV/00216224:14110/14:00075516!RIV15-MSM-14110___
n3:aktivita
n6:I n6:N
n3:aktivity
I, N
n3:cisloPeriodika
2
n3:dodaniDat
n5:2015
n3:domaciTvurceVysledku
n7:2973561 n7:6141994
n3:druhVysledku
n11:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
12912
n3:idVysledku
RIV/00216224:14110/14:00075516
n3:jazykVysledku
n18:eng
n3:klicovaSlova
Haemophilia; NovoSeven (R); rFVIIa; High dose; Costs; Time to treatment
n3:klicoveSlovo
n4:NovoSeven%20%28R%29 n4:High%20dose n4:rFVIIa n4:Haemophilia n4:Costs n4:Time%20to%20treatment
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[0581D326CD06]
n3:nazevZdroje
Thrombosis Research
n3:obor
n16:FD
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n5:2014
n3:svazekPeriodika
133
n3:tvurceVysledku
Mesterton, Johan Penka, Miroslav Ovesná, Petra Cetkovský, Petr Lindgren, Peter Salaj, Peter Kubes, Radovan Capova, Irena
n3:wos
000329572600007
s:issn
0049-3848
s:numberOfPages
6
n13:doi
10.1016/j.thromres.2013.11.002
n10:organizacniJednotka
14110